MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

计划入组 5 人 · 首次发布于 2022 年 10 月 19 日

A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

计划入组 14 人 · 首次发布于 2019 年 7 月 1 日

Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).

首次发布于 2026 年 6 月 30 日

Gaucher(CENTOGENE )

gaucher program

Recombinant Ebola Virus Disease Vaccine(Adenovirus Type 5 Vector)

Rx

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Yuhan's YH35995 Receives FDA Orphan Drug Designation for Gaucher Disease Treatment

Spur Therapeutics to Present Long-Term Durability Data for Phase 3-Ready Gaucher Disease Gene Therapy

Spur Therapeutics to Present Two-Year Clinical Data for FLT201 Gene Therapy in Gaucher Disease at WORLDSymposium